Our own manufacturing plants: 

The industrial Tit Mellil plant ( Cooper Pharma)


The factory occupies an area of20,000 square meters and has about 500 employees.. The Tit Mellil unit ensures manufacturing of injectables, solids, liquids and paste forms. The site is certified ISO 9001: 2000, GMP, AFSSAPS and Saudi FDA. Over 42 million units were produced in 2016 This site works with an ongoing process of continuous improvement of its capabilities with the renewal of equipments at the cutting edge of technology.

The Bouskoura industrial plant (MC Pharma)

On this site created in 2007, Cooper Pharma manufactures mostly effervescent tablets according to specific standards and conditions as the use of a dry air system.

Cooper Pharma holds a strategic participation in MC Pharma.




Gynebio Pharma (industriel plan at Sapino)

This industrial site, operational at the end of 2017, will be the first site dedicated to the manufacture of contraceptive hormones, respecting EU & US standards in the Africa and Middle East region.




IDC Pharma

Cooper Pharma has also a laboratory dedicated to incremental research and development.
Its mission is to make Galenic development:

Medicines with value-added formulations

“Generics +”


Cooper East Africa

Begining of the operations expected in 2019 at Kigali, Rwanda.




Cooper West Africa

Begining of the operations expected in 2019 at Abidjan, Ivory Coast.




Our industrial Joint Ventures: 

Joint Venture with Cipla and PHI, to produce medicines dedicated to respiratory diseases in Morocco. The manufacture of MDIs (inhalers / aerosols) will be a first in Morocco.

Joint Venture with Spimaco, leader of the Saudi pharmaceutical industry and Arac for the plant Dammam Pharma in Dammam/Saoudi Arabia.

Joint Venture with Spimaco for the plant Ipharma in Tangier, Morocco . Ipharma is in the process of creating a new industrial site in the casablanca region.